Eris Lifesciences appoints Akhil Awasthi as additional director
- Akhil Awasthi appointed as Additional Director (Non-executive, Independent)
- Effective date set for September 26, 2026, with a five-year term
- Board approved the appointment on September 21, 2026
- Role subject to final approval by company members
*this image is generated using AI for illustrative purposes only.
Eris Lifesciences has appointed Akhil Awasthi as an additional non-executive, independent director. The appointment is effective from September 26, 2026.
The Board of Directors approved the move on September 21, 2026, based on the recommendation of the Nomination and Remuneration Committee. The decision was formalized through a circular resolution issued the same day.
Appointment Details
Mr. Awasthi will serve a term of five years. His appointment as an Additional Director is subject to the approval of the company’s members at a general meeting.
| Particulars | Details |
|---|---|
| Appointee | Akhil Awasthi (DIN: 00148350) |
| Role | Additional Director (Non-executive, Independent) |
| Effective Date | September 26, 2026 |
| Term | Five years |
| Approval Status | Subject to member approval |
Profile and Governance
Mr. Awasthi brings over three decades of experience in private equity, investment management, healthcare, and corporate governance. He previously served as Founding Managing Partner and Investment Committee Member of Tata Capital Growth Fund. He also held the position of Partner at Baring Private Equity Partners (India) Ltd.
The filing confirms that Mr. Awasthi is not related to any existing director of the company. He is not debarred from holding the office of Director by SEBI or any other authority. The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Historical Stock Returns for Eris Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.40% | -2.91% | -2.53% | +0.60% | -19.56% | 0.0% |
How might Akhil Awasthi's extensive private equity and healthcare investment background influence Eris Lifesciences' strategic M&A decisions in the coming years?
What specific governance reforms or board committee roles is Mr. Awasthi expected to prioritize during his five-year tenure to enhance corporate oversight?
Could this appointment signal a shift in Eris Lifesciences' capital allocation strategy, particularly regarding leverage management or dividend policies?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
